Core Insights - The company reported a third-quarter revenue of 190 million, a year-on-year decrease of 12.32% [1] - The net profit for the third quarter was a loss of 15.73 million, representing a decline of 129.02% [1] - For the first three quarters, the company achieved a revenue of 681 million, down 13.11% year-on-year [1] - The net profit for the first three quarters was a loss of 44.82 million, a significant decline of 714.77% [1]

证券代码：300255 证券简称：常山药业 公告编号：2025-44 河北常山生化药业股份有限公司 关于修订《公司章程》及相关议事规则的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 河北常山生化药业股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日 召开第六届董事会第四次会议，审议并通过了《关于修订<公司章程>及相关议 事规则的议案》，具体情况如下： 一、修订《公司章程》及相关议事规则的原因 为全面贯彻落实最新法律法规和监管规定要求，进一步规范公司运作机制， 完善公司治理结构，根据《公司法》《上市公司章程指引》及《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》等最新法律法规和 规范性文件的要求，并结合公司实际情况，公司对《公司章程》及其附件《股东 会议事规则》《董事会议事规则》进行修订。 二、本次《公司章程》修订情况 | 原章程 | 修订后章程 | | --- | --- | | 指公司的总经理、副总经理、财务总监、及 | 指公司的总经理、副总经理、财务总监、董 | | 董事会秘书。 | 事会秘书和本章程规定的 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-42 第六届监事会第四次会议决议公告 本公司及其监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 河北常山生化药业股份有限公司（以下简称"公司"）第六届监事会第四次 会议于2025年10月29日在公司办公楼会议室以现场方式召开。本次会议于2025 年 10 月 19 日以邮件或直接送达的方式确保每一位监事收到本次会议通知。与会 的各位监事均已知悉与所议事项相关的必要信息。会议应参与表决监事 3 名，实 际参与表决监事 3 名。本次会议由公司监事会主席宗庆松先生主持，符合《公司 法》及《公司章程》等规定。 二、监事会会议审议情况 河北常山生化药业股份有限公司 1．审议通过《关于<公司 2025 年第三季度报告>的议案》 监事会认为董事会编制和审核公司 2025 年第三季度报告的程序符合法律、 行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际 情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意；0 票反对；0 票弃权。 三、备查文件 1．第六届 ...

Financial Performance - Q3 2025 revenue was CNY 189,613,515.77, a decrease of 12.32% year-over-year[4] - Net profit attributable to shareholders was CNY -15,728,432.84, down 129.02% compared to the same period last year[4] - Basic and diluted earnings per share were both CNY -0.02, reflecting a decline of 133.33% year-over-year[4] - Total operating revenue decreased to ¥681,221,459.23 from ¥784,021,902.08, representing a decline of approximately 13.1% year-over-year[19] - Net profit for the period was -¥56,983,632.04, compared to -¥27,806,023.52 in the previous period, indicating a worsening of approximately 104.1%[20] - The total comprehensive income for the period was -¥57,237,822.00, compared to -¥27,804,018.75 in the previous period, indicating a decline of approximately 106.5%[20] - The company reported a basic earnings per share of -¥0.05, compared to ¥0.01 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,657,584,588.98, an increase of 2.98% from the end of the previous year[4] - The total assets of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. as of September 30, 2025, amounted to CNY 4,657,584,588.98, an increase from CNY 4,522,760,540.58 at the beginning of the period[16] - Current assets totaled CNY 2,077,304,073.35, up from CNY 2,002,412,631.48 at the beginning of the period, reflecting a growth of approximately 3.9%[16] - Total liabilities rose to CNY 3,179,083,140.13 from CNY 2,987,021,269.73, reflecting an increase of about 6.4%[17] - The company's equity remained stable with total equity at CNY 1,478,501,448.85, unchanged from the previous period[17] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 142,350,749.85, down 5.32%[4] - Cash flow from operating activities generated ¥142,350,749.85, down from ¥150,346,631.17, a decrease of about 5.3% year-over-year[21] - Cash flow from investing activities increased by 39.04% year-over-year, mainly due to reduced cash payments for fixed assets and other long-term assets[10] - Net cash flow from investing activities was -$72.1 million, an improvement from -$118.3 million year-over-year[22] - Cash inflow from financing activities totaled $2.07 billion, compared to $1.71 billion in the previous year[22] - Cash outflow from financing activities was $2.13 billion, up from $1.65 billion year-over-year[22] - Net cash flow from financing activities was -$61.9 million, a decline from a positive $51.0 million in the previous year[22] - The net increase in cash and cash equivalents was $11.2 million, down from $83.3 million year-over-year[22] - The ending balance of cash and cash equivalents was $247.0 million, compared to $314.2 million at the end of the previous year[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,618[11] Strategic Focus - The company plans to continue focusing on R&D for new products and technologies to enhance market competitiveness[15] - Future guidance indicates a strategic emphasis on market expansion and potential mergers and acquisitions to drive growth[15] Operational Efficiency - Sales expenses decreased by 64.22% year-over-year, attributed to the inclusion of products in national procurement and adjustments in sales strategy[9] - Investment income increased by 100.00% year-over-year due to gains from the disposal of a subsidiary[9] - Research and development expenses increased slightly to ¥24,568,492.79 from ¥23,438,244.55, reflecting a growth of approximately 4.8%[19] - Other income decreased significantly to ¥5,567,369.76 from ¥30,589,042.11, a decline of about 81.8% year-over-year[19] - The company recorded credit impairment losses of ¥7,201,497.18, up from ¥531,492.70, marking an increase of approximately 1255.5% year-over-year[20] Inventory and Receivables - Accounts receivable rose to CNY 310,502,510.21 from CNY 253,625,332.05, indicating an increase of approximately 22.4%[16] - Inventory decreased to CNY 1,341,817,413.22 from CNY 1,385,747,770.05, showing a decline of about 3.2%[16] Borrowings - Short-term borrowings increased by 47.98% compared to the beginning of the period, indicating a rise in borrowing[7] - Short-term borrowings increased significantly to CNY 1,313,433,777.78 from CNY 887,546,719.51, marking an increase of approximately 48.0%[17] Audit Status - The third quarter financial report was not audited[23]

Market Overview - The chemical pharmaceutical sector increased by 1.72% on October 27, with Sunflower leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Top Gainers - Sunflower (300111) closed at 9.43, up 19.97% with a trading volume of 3.28 million shares [1] - Changshan Pharmaceutical (300255) closed at 58.09, up 13.61% with a trading volume of 483,300 shares [1] - Lianhuan Pharmaceutical (600513) closed at 20.59, up 7.13% with a trading volume of 425,400 shares [1] - Other notable gainers include Saint Noble Bio (688117) and Meinuohua (603538), with increases of 6.61% and 6.50% respectively [1] Top Losers - Tonghe Pharmaceutical (300636) closed at 8.37, down 4.89% with a trading volume of 260,000 shares [2] - ST Suwu (600200) closed at 1.01, down 4.72% with a trading volume of 154,800 shares [2] - Kangzhiyue Pharmaceutical (300086) closed at 6.90, down 4.30% with a trading volume of 454,200 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 1.017 billion yuan from institutional investors, while retail investors experienced a net outflow of 82.02 million yuan [2][3] - Major stocks like Sunflower and Lianhuan Pharmaceutical attracted significant institutional investment, with Sunflower seeing a net inflow of 583 million yuan [3]

Core Points - The Shanghai Composite Index closed at 3991.35 points, above the five-day moving average, with an increase of 1.04% [1] - The total trading volume of A-shares reached 1,576.01 billion yuan [1] - A total of 722 A-shares have prices that surpassed the five-day moving average, indicating a positive market trend [1] Summary by Category Stock Performance - Notable stocks with significant deviations from the five-day moving average include Longzhu Technology (15.40%), Yongfu Co., Ltd. (14.16%), and Pioneer New Materials (13.24%) [1] - Longzhu Technology saw a daily increase of 20.22%, with a turnover rate of 12.58% [1] - Yongfu Co., Ltd. increased by 19.98%, with a turnover rate of 9.37% [1] - Pioneer New Materials rose by 18.01%, with a turnover rate of 27.91% [1] Market Trends - Stocks with smaller deviations from the five-day moving average include Aibulu, Xinhua Medical, and Yunnan Baiyao, which have just crossed the five-day moving average [1] - The overall market sentiment appears to be bullish, as indicated by the number of stocks surpassing their five-day moving averages [1] Trading Data - The trading data for stocks that broke the five-day moving average includes various metrics such as daily price changes, turnover rates, and the latest prices compared to the five-day moving average [1][2] - The table provided lists multiple stocks with their respective performance metrics, highlighting the active trading environment [2]

Market Overview - The Shanghai Composite Index is at 3981.95 points, above the five-day moving average, with an increase of 0.80% [1] - The total trading volume of A-shares is 12,201.25 billion yuan [1] Stocks Performance - A total of 495 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Cheng Tian Wei Ye (300689) with a deviation rate of 8.57% and a daily increase of 11.21% [1] - Xian Feng Xin Cai (300163) with a deviation rate of 8.45% and a daily increase of 11.63% [1] - Wan Lang Ci Su (603150) with a deviation rate of 7.89% and a daily increase of 10.01% [1] Detailed Stock Data - The following stocks have notable performance metrics: - Cheng Tian Wei Ye: Latest price 57.14 yuan, five-day moving average 52.63 yuan [1] - Xian Feng Xin Cai: Latest price 4.03 yuan, five-day moving average 3.72 yuan [1] - Wan Lang Ci Su: Latest price 41.42 yuan, five-day moving average 38.39 yuan [1] - Other stocks with significant performance include: - Lu Lian Ke Ji (301606) with a daily increase of 9.30% and a deviation rate of 7.03% [1] - Sheng Tong Neng Yuan (001331) with a daily increase of 9.98% and a deviation rate of 6.81% [1]

Core Viewpoint - The continuous decline in the number of shareholders for certain companies indicates a trend of increasing concentration of shares, with 69 companies experiencing a decrease for more than three consecutive periods, and some like Yongli Co. seeing a drop for nine periods [1]. Group 1: Shareholder Information - As of October 20, 391 companies reported their latest shareholder numbers, with notable declines in companies such as Yongli Co. (23,968 shareholders, down 17.14%) and ST Emergency (51,994 shareholders, down 33.91%) [1]. - The trend of decreasing shareholder numbers suggests a concentration of shares among fewer investors, which may impact stock liquidity and volatility [1]. Group 2: Market Performance - Among the companies with declining shareholder numbers, 25 saw their stock prices increase, while 44 experienced declines, with notable gainers including Jingquanhua (up 54.40%), China Merchants Energy (up 31.12%), and Changshan Pharmaceutical (up 16.80%) [2]. - 14 companies outperformed the Shanghai Composite Index, with Jingquanhua, China Merchants Energy, and Changshan Pharmaceutical achieving relative returns of 51.95%, 29.68%, and 14.35%, respectively [2]. Group 3: Industry Analysis - The industries with the highest concentration of companies experiencing declining shareholder numbers include machinery, electronics, and computers, with 12, 9, and 5 companies respectively [2]. - The distribution of these companies shows that 32 are listed on the main board and 37 on the ChiNext board, indicating a diverse range of sectors affected by this trend [2]. Group 4: Institutional Activity - In the past month, 9 companies with declining shareholder numbers were subject to institutional research, with frequent investigations seen in companies like Boshi Jie (2 times) [2]. - The companies attracting the most institutional interest include Sanxia Tourism (16 institutions), Zhongci Electronics (10 institutions), and Boshi Jie (8 institutions) [2]. Group 5: Performance Metrics - Four companies have reported their Q3 earnings, with Yanjing Beer showing the highest year-on-year net profit growth of 37.45% [3]. - Among companies with earnings forecasts, Tongxing Technology is expected to have a net profit median of 57.33 million, reflecting a year-on-year increase of 194.04% [3].

Group 1 - The company, Changshan Pharmaceutical, stated on October 21 that it will announce any significant progress regarding the上市申请 (listing application) for Aibennapeptide according to relevant regulations [2]

Group 1 - The company, Changshan Pharmaceutical, reported that as of October 20, 2025, the number of its shareholders is 45,431 [2]